Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Core Insights - Zenas BioPharma is advancing its obexelimab development program, with key clinical trials ongoing for autoimmune diseases, including the Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease (IgG4-RD) and the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis (RMS) [1][2][4] Clinical Trials - The Phase 3 INDIGO trial for IgG4-RD is the largest clinical trial conducted for this condition, with topline results expected around year-end 2025 [1][4] - Enrollment for the Phase 2 MoonStone trial in RMS has been completed, with results anticipated in early Q4 2025 [1][4] - The Phase 2 SunStone trial for Systemic Lupus Erythematosus (SLE) is expected to complete enrollment by year-end 2025, with topline results projected for mid-2026 [1][4] Financial Overview - As of June 30, 2025, Zenas BioPharma reported cash, cash equivalents, and investments totaling $274.9 million, which is expected to fund operations into Q4 2026 [1][4][16] - Research and development (R&D) expenses for Q2 2025 were $43.0 million, an increase from $33.8 million in Q2 2024, primarily due to higher clinical development costs for obexelimab [4][9] - General and administrative (G&A) expenses rose to $12.1 million in Q2 2025 from $5.9 million in Q2 2024, attributed to increased personnel costs and pre-commercialization activities [9][14] Product Information - Obexelimab is a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, designed to inhibit B cell function without depleting them, potentially addressing chronic autoimmune diseases effectively [5][7] - The drug has shown pharmacologic activity in five completed clinical trials involving 198 subjects, indicating its potential as a potent B cell inhibitor [6]